 By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals NASDAQ:EYEG is sticking to its business plan, despite any disruption from the pandemic. Meetings with regulators are on the schedule, and preparatory work for its approval filing continues. First quarter results were in-line with estimates. Research and development rose to 0.9 million in the quarter, 